Neurobiology of Sleep and Wakefulness
A dynamic process between arousal-promoting and sleep-promoting systems mediates sleep and wakefulness. The ascending reticular activating system actively maintains wakefulness, which consists of cholinergic projections from the pedunculopontine and laterodorsal tegmentum, and monoaminergic input from the locus coeruleus, dorsal raphe, and tuberomammillary nuclei, as well as the orexin system of the lateral hypothalamus, which prevents unwanted shifts toward sleep (Luo et al., 2023). Sleep onset occurs when gamma-aminobutyric acid and galanin are released in the ventrolateral preoptic nucleus, inhibiting arousal centers and lowering cortical activity. The suprachiasmatic nucleus coordinates circadian timing and regulates pineal melatonin secretion and sleep-wake rhythms in response to environmental light-dark cycles. It is this coordinated balance between the circadian and homeostatic processes that ultimately defines the stability of sleep and alertness throughout the 24-hour24-hour cycle.
Difference Between Insomnia and Chronic Insomnia
Insomnia is a persistent problem characterized by difficulty falling asleep, staying asleep, or premature waking, even after time to rest. Diagnostic criteria highlight related impairment during the day, including fatigue, irritability, poor concentration, or poor work performance. Chronic insomnia is characterized by symptoms occurring at least 3 days a week and for at least 3 months, without another primary sleep, medical, or psychiatric disorder (McNamara et al., 2025). The chronic form presents with conditioned hyperarousal, in which patients come to view the sleep environment as wakefulness and tend to report thoughts racing, anticipatory anxiety about not falling asleep, and physiologic alertness high towards bedtime. This constant hyperarousal continues with long-term sleep disruption despite the stressor precipitating it being resolved.
Comparison of Melatonergic and Serotonergic Hypnotics
Melatoninergic hypnotics directly activate MT1 and MT2 receptors in the suprachiasmatic nucleus, thereby adjusting circadian phase and inducing sleep. They exhibit low levels of next-day sedation, low abuse risk, and minimal influence on sleep architecture. They are suitable for circadian rhythm sleep-wake disorders and for geriatric patients (Żełabowski et al., 2025). Low-dose trazodone is a serotonergic hypnotic that promotes sleep by altering 5-HT pathways, which indirectly inhibit arousal systems via gamma-aminobutyric acid. When insomnia exists alongside depression or anxiety, they tend to be used since their serotonergic effect can treat mood problems as well as offer a sedative potential impact. These classes frequently vary in selection based on the presence or absence of an insomnia that is primarily driven by circadian or comorbid mood or anxiety symptoms.
Pros and Cons of Histamine Antagonists as Hypnotics
First-generation antihistamine blockers, especially H1 receptor antagonists, induce sleep by inhibiting histaminergic signaling in the tuberomammillary nucleus, which helps maintain cortical arousal. Their pros are that they have a quick onset of sedation and are widely available over the counter, which makes their short-term use everyday in acute insomnia (Costa et al., 2025). Nevertheless, such drugs have a high anticholinergic effect that may cause difficulties in cognition, create urinary retention, and risk falls in older adults. Within a few days, tolerance to the sedative effect may develop, leading to reduced impact and poor sleep architecture. We should therefore not use the histamine antagonists to treat chronic insomnia even though they are readily available.
References
Costa, A., Di Bonaventura, E. M., Botticelli, L., Eramo, B., Gaetani, S., Passani, M. B., Cifani, C., Di Bonaventura, M. V. M., & Provensi, G. (2025). Brain histaminergic system: An emerging target for the treatment of feeding and eating-related disorders. Pharmacological Research, 221, 107949. https://doi.org/10.1016/j.phrs.2025.107949
Luo, Y., Li, Y., & Yuan, J. (2023). The regulation of the pedunculopontine tegmental nucleus in sleep–wake states. Sleep and Biological Rhythms, 22(1), 5–11. https://doi.org/10.1007/s41105-023-00489-7
McNamara, S., Spurling, B. C., & Bollu, P. C. (2025, March 28). Chronic insomnia. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK526136/
Żełabowski, K., Pichowicz, W., Skowron, I., Szwach, J., Biedka, K., Wesołowski, M., Błaszczyk, K., Ziobro, O., Petrov, W., Kukula-Koch, W., & Chłopaś-Konowałek, A. (2025). The efficacy of melatoninergic receptor agonists used in clinical practice in insomnia treatment: melatonin, tasimelteon, ramelteon, agomelatine, and selected herbs. Molecules, 30(18), 3814. https://doi.org/10.3390/molecules30183814
CLICK HERE TO ORDER A PLAGIARISM – FREE PAPER
How do the neurobiological mechanisms regulating sleep and wakefulness influence the development and management of insomnia and chronic insomnia, and how do different classes of hypnotics (melatonergic, serotonergic, and histamine antagonists) compare in their effectiveness, mechanisms, and risks? Please support your response with scholarly sources published within the last 5 years.